Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 241

1.

Oligoarginine Peptides, a New Family of nAChR Inhibitors.

Lebedev D, Kryukova E, Ivanov I, Egorova N, Timofeev N, Spirova E, Tufanova E, Siniavin A, Kudryavtsev D, Kasheverov I, Zouridakis M, Katsarava R, Zavradashvili N, Iagorshvili I, Tzartos S, Tsetlin V.

Mol Pharmacol. 2019 Sep 6. pii: mol.119.117713. doi: 10.1124/mol.119.117713. [Epub ahead of print]

2.

Crystal Structure of the Monomeric Extracellular Domain of α9 Nicotinic Receptor Subunit in Complex With α-Conotoxin RgIA: Molecular Dynamics Insights Into RgIA Binding to α9α10 Nicotinic Receptors.

Zouridakis M, Papakyriakou A, Ivanov IA, Kasheverov IE, Tsetlin V, Tzartos S, Giastas P.

Front Pharmacol. 2019 May 1;10:474. doi: 10.3389/fphar.2019.00474. eCollection 2019.

3.

Myasthenia gravis.

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM.

Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Review.

PMID:
31048702
4.

Retraction Note to: Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.

Hong Y, Skeie GO, Zisimopoulou P, Karagiorgou K, Tzartos SJ, Gao X, Yue YX, Romi F, Zhang X, Li HF, Gilhus NE.

J Neurol. 2019 Jun;266(6):1555. doi: 10.1007/s00415-019-09292-2.

PMID:
30972499
5.

The putative polysaccharide deacetylase Ba0331: cloning, expression, crystallization and structure determination.

Andreou A, Giastas P, Arnaouteli S, Tzanodaskalaki M, Tzartos SJ, Bethanis K, Bouriotis V, Eliopoulos EE.

Acta Crystallogr F Struct Biol Commun. 2019 Apr 1;75(Pt 4):312-320. doi: 10.1107/S2053230X19001766. Epub 2019 Apr 3.

PMID:
30950833
6.

Orthosteric and/or Allosteric Binding of α-Conotoxins to Nicotinic Acetylcholine Receptors and Their Models.

Kryukova EV, Ivanov IA, Lebedev DS, Spirova EN, Egorova NS, Zouridakis M, Kasheverov IE, Tzartos SJ, Tsetlin VI.

Mar Drugs. 2018 Nov 22;16(12). pii: E460. doi: 10.3390/md16120460.

7.

Characterization of the thymus in Lrp4 myasthenia gravis: Four cases.

Koneczny I, Rennspiess D, Marcuse F, Dankerlui N, Abdul Hamid M, Mané-Damas M, Maessen J, Van Schil P, Saxena A, Zisimopoulou P, Lazaridis K, Woodhall M, Karagiorgou K, Tzartos J, Tzartos S, De Baets MH, Molenaar PC, Marx A, Zur Hausen A, Losen M, Martinez-Martinez P.

Autoimmun Rev. 2019 Jan;18(1):50-55. doi: 10.1016/j.autrev.2018.07.011. Epub 2018 Nov 8.

8.

Immunostick ELISA for rapid and easy diagnosis of myasthenia gravis.

Trakas N, Tzartos SJ.

J Immunol Methods. 2018 Sep;460:107-112. doi: 10.1016/j.jim.2018.06.016. Epub 2018 Jul 2.

PMID:
30056940
9.

Nicotinic acetylcholine receptors.

Wonnacott S, Bermudez I, Millar NS, Tzartos SJ.

Br J Pharmacol. 2018 Jun;175(11):1785-1788. doi: 10.1111/bph.14209.

10.

Structures of the Peptidoglycan N-Acetylglucosamine Deacetylase Bc1974 and Its Complexes with Zinc Metalloenzyme Inhibitors.

Giastas P, Andreou A, Papakyriakou A, Koutsioulis D, Balomenou S, Tzartos SJ, Bouriotis V, Eliopoulos EE.

Biochemistry. 2018 Feb 6;57(5):753-763. doi: 10.1021/acs.biochem.7b00919. Epub 2018 Jan 5.

PMID:
29257674
11.

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient.

Saxena A, Stevens J, Cetin H, Koneczny I, Webster R, Lazaridis K, Tzartos S, Vrolix K, Nogales-Gadea G, Machiels B, Molenaar PC, Damoiseaux J, De Baets MH, Simon-Keller K, Marx A, Vincent A, Losen M, Martinez-Martinez P.

Sci Rep. 2017 Oct 31;7(1):14426. doi: 10.1038/s41598-017-14350-8.

12.

Antibodies to aquaporins are frequent in patients with primary Sjögren's syndrome.

Tzartos JS, Stergiou C, Daoussis D, Zisimopoulou P, Andonopoulos AP, Zolota V, Tzartos SJ.

Rheumatology (Oxford). 2017 Dec 1;56(12):2114-2122. doi: 10.1093/rheumatology/kex328.

PMID:
28968830
13.

Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.

Lazaridis K, Dalianoudis I, Baltatzidi V, Tzartos SJ.

J Neuroimmunol. 2017 Nov 15;312:24-30. doi: 10.1016/j.jneuroim.2017.09.001. Epub 2017 Sep 6.

PMID:
28912035
14.

Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Cordts I, Bodart N, Hartmann K, Karagiorgou K, Tzartos JS, Mei L, Reimann J, Van Damme P, Rivner MH, Vigneron A, Weis J, Schulz JB, Tzartos SJ, Claeys KG.

J Neurol. 2017 Jun;264(6):1193-1203. doi: 10.1007/s00415-017-8514-z. Epub 2017 May 17.

PMID:
28516329
15.

Multiple antibody detection in 'seronegative' myasthenia gravis patients.

Hong Y, Zisimopoulou P, Trakas N, Karagiorgou K, Stergiou C, Skeie GO, Hao HJ, Gao X, Owe JF, Zhang X, Yue YX, Romi F, Wang Q, Li HF, Gilhus NE, Tzartos SJ.

Eur J Neurol. 2017 Jun;24(6):844-850. doi: 10.1111/ene.13300. Epub 2017 May 4.

PMID:
28470860
16.

Understanding structure-function relationships of the human neuronal acetylcholine receptor: insights from the first crystal structures of neuronal subunits.

Giastas P, Zouridakis M, Tzartos SJ.

Br J Pharmacol. 2018 Jun;175(11):1880-1891. doi: 10.1111/bph.13838. Epub 2017 Jun 20. Review.

17.

Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.

Hong Y, Skeie GO, Zisimopoulou P, Karagiorgou K, Tzartos SJ, Gao X, Yue YX, Romi F, Zhang X, Li HF, Gilhus NE.

J Neurol. 2017 May;264(5):955-962. doi: 10.1007/s00415-017-8478-z. Epub 2017 Mar 31. Retraction in: J Neurol. 2019 Apr 11;:.

PMID:
28364296
18.

Recurrent tumefactive demyelinating lesions: a pathological study.

Türkoğlu R, Lassmann H, Aker FV, Tzartos J, Tzartos S, Tüzün E.

Clin Neuropathol. 2017 Jul/Aug;36(4):195-198. doi: 10.5414/NP301005. No abstract available.

PMID:
28211783
19.

Characterization of a reproducible rat EAMG model induced with various human acetylcholine receptor domains.

Lazaridis K, Baltatzidi V, Trakas N, Koutroumpi E, Karandreas N, Tzartos SJ.

J Neuroimmunol. 2017 Feb 15;303:13-21. doi: 10.1016/j.jneuroim.2016.12.011. Epub 2016 Dec 21.

PMID:
28038891
20.

IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.

Koneczny I, Stevens JA, De Rosa A, Huda S, Huijbers MG, Saxena A, Maestri M, Lazaridis K, Zisimopoulou P, Tzartos S, Verschuuren J, van der Maarel SM, van Damme P, De Baets MH, Molenaar PC, Vincent A, Ricciardi R, Martinez-Martinez P, Losen M.

J Autoimmun. 2017 Feb;77:104-115. doi: 10.1016/j.jaut.2016.11.005. Epub 2016 Dec 10.

21.

The role of carbohydrate component of recombinant α7 nicotinic acetylcholine receptor extracellular domain in its immunogenicity and functional effects of resulting antibodies.

Lykhmus O, Koval L, Pastuhova D, Zouridakis M, Tzartos S, Komisarenko S, Skok M.

Immunobiology. 2016 Dec;221(12):1355-1361. doi: 10.1016/j.imbio.2016.07.012. Epub 2016 Jul 25.

PMID:
27498631
22.

Crystal structure of a human neuronal nAChR extracellular domain in pentameric assembly: Ligand-bound α2 homopentamer.

Kouvatsos N, Giastas P, Chroni-Tzartou D, Poulopoulou C, Tzartos SJ.

Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9635-40. doi: 10.1073/pnas.1602619113. Epub 2016 Aug 4.

23.

MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.

Küçükerden M, Huda R, Tüzün E, Yılmaz A, Skriapa L, Trakas N, Strait RT, Finkelman FD, Kabadayı S, Zisimopoulou P, Tzartos S, Christadoss P.

J Neuroimmunol. 2016 Jun 15;295-296:84-92. doi: 10.1016/j.jneuroim.2016.04.003. Epub 2016 Apr 11.

PMID:
27235354
24.

Myasthenia gravis - autoantibody characteristics and their implications for therapy.

Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S.

Nat Rev Neurol. 2016 May;12(5):259-68. doi: 10.1038/nrneurol.2016.44. Epub 2016 Apr 22. Review.

PMID:
27103470
25.

Titin antibodies in "seronegative" myasthenia gravis--A new role for an old antigen.

Stergiou C, Lazaridis K, Zouvelou V, Tzartos J, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Gilhus NE, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Bogomolovas J, Labeit D, Labeit S, Tzartos SJ.

J Neuroimmunol. 2016 Mar 15;292:108-15. doi: 10.1016/j.jneuroim.2016.01.018. Epub 2016 Jan 27.

PMID:
26943968
26.

Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice.

Ulusoy C, Zibandeh N, Yıldırım S, Trakas N, Zisimopoulou P, Küçükerden M, Tașlı H, Tzartos S, Göker K, Tüzün E, Akkoç T.

J Neuroinflammation. 2015 Dec 9;12:231. doi: 10.1186/s12974-015-0451-0.

27.

Reduced muscle mitochondrial enzyme activity in MuSK-immunized mice.

Özkök E, Durmuş H, Yetimler B, Taşlı H, Trakas N, Ulusoy C, Lagoumintzis G, Tzartos S, Tüzün E.

Clin Neuropathol. 2015 Nov-Dec;34(6):359-63. doi: 10.5414/NP300875.

PMID:
26365462
28.

MuSK autoantibodies in myasthenia gravis detected by cell based assay--A multinational study.

Tsonis AI, Zisimopoulou P, Lazaridis K, Tzartos J, Matsigkou E, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Behin A, Sharshar T, De Baets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Casasnovas Pons C, Pitha J, Jakubíkova M, Hanisch F, Tzartos SJ.

J Neuroimmunol. 2015 Jul 15;284:10-7. doi: 10.1016/j.jneuroim.2015.04.015. Epub 2015 Apr 27.

PMID:
26025053
29.

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.

Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F, Saruhan-Direskeneli G.

PLoS One. 2015 Apr 20;10(4):e0123546. doi: 10.1371/journal.pone.0123546. eCollection 2015.

30.

Inflammation decreases the level of alpha7 nicotinic acetylcholine receptors in the brain mitochondria and makes them more susceptible to apoptosis induction.

Lykhmus O, Gergalova G, Zouridakis M, Tzartos S, Komisarenko S, Skok M.

Int Immunopharmacol. 2015 Nov;29(1):148-51. doi: 10.1016/j.intimp.2015.04.007. Epub 2015 Apr 15.

PMID:
25887272
31.

Two Putative Polysaccharide Deacetylases Are Required for Osmotic Stability and Cell Shape Maintenance in Bacillus anthracis.

Arnaouteli S, Giastas P, Andreou A, Tzanodaskalaki M, Aldridge C, Tzartos SJ, Vollmer W, Eliopoulos E, Bouriotis V.

J Biol Chem. 2015 May 22;290(21):13465-78. doi: 10.1074/jbc.M115.640029. Epub 2015 Mar 30.

32.

α7 Nicotinic acetylcholine receptor-specific antibody induces inflammation and amyloid β42 accumulation in the mouse brain to impair memory.

Lykhmus O, Voytenko L, Koval L, Mykhalskiy S, Kholin V, Peschana K, Zouridakis M, Tzartos S, Komisarenko S, Skok M.

PLoS One. 2015 Mar 27;10(3):e0122706. doi: 10.1371/journal.pone.0122706. eCollection 2015.

33.

Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Losen M, Martinez-Martinez P, Molenaar PC, Lazaridis K, Tzartos S, Brenner T, Duan RS, Luo J, Lindstrom J, Kusner L.

Exp Neurol. 2015 Aug;270:18-28. doi: 10.1016/j.expneurol.2015.03.010. Epub 2015 Mar 18.

34.

Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs.

Kusner LL, Losen M, Vincent A, Lindstrom J, Tzartos S, Lazaridis K, Martinez-Martinez P.

Exp Neurol. 2015 Aug;270:3-10. doi: 10.1016/j.expneurol.2015.02.025. Epub 2015 Mar 3.

35.

Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor.

Azam L, Papakyriakou A, Zouridakis M, Giastas P, Tzartos SJ, McIntosh JM.

Mol Pharmacol. 2015 May;87(5):855-64. doi: 10.1124/mol.114.096511. Epub 2015 Mar 4. Erratum in: Mol Pharmacol. 2016 Oct;90(4):415-7.

36.

Guidelines for standard preclinical experiments in the mouse model of myasthenia gravis induced by acetylcholine receptor immunization.

Tuzun E, Berrih-Aknin S, Brenner T, Kusner LL, Le Panse R, Yang H, Tzartos S, Christadoss P.

Exp Neurol. 2015 Aug;270:11-7. doi: 10.1016/j.expneurol.2015.02.009. Epub 2015 Feb 16.

PMID:
25697844
37.

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.

Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V, Clairac G, Tzartos S, Fadel E, Eymard B, Fuchs S, Souroujon MC, Berrih-Aknin S.

Acta Neuropathol Commun. 2015 Jan 15;3:1. doi: 10.1186/s40478-014-0179-6.

38.

Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains.

Lazaridis K, Evaggelakou P, Bentenidi E, Sideri A, Grapsa E, Tzartos SJ.

J Neuroimmunol. 2015 Jan 15;278:19-25. doi: 10.1016/j.jneuroim.2014.12.001. Epub 2014 Dec 3.

PMID:
25595248
39.

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.

Avidan N, Le Panse R, Harbo HF, Bernasconi P, Poulas K, Ginzburg E, Cavalcante P, Colleoni L, Baggi F, Antozzi C, Truffault F, Horn-Saban S, Pöschel S, Zagoriti Z, Maniaol A, Lie BA, Bernard I, Saoudi A, Illes Z, Casasnovas Pons C, Melms A, Tzartos S, Willcox N, Kostera-Pruszczyk A, Tallaksen C, Mantegazza R, Berrih-Aknin S, Miller A.

Ann Clin Transl Neurol. 2014 May;1(5):329-39. doi: 10.1002/acn3.51. Epub 2014 Apr 11.

40.

LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.

Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P, Tsonis A, Thomaidis T, Lauria G, Andreetta F, Mantegazza R, Tzartos SJ.

Ann Clin Transl Neurol. 2014 Feb;1(2):80-7. doi: 10.1002/acn3.26. Epub 2013 Dec 30.

41.

Authors' reply to Wang et al. comment on "Parkinson's disease associated with myasthenia gravis and rheumatoid arthritis".

Zis P, Tzartos SJ, Tavernarakis A.

Neurol Sci. 2015 Mar;36(3):487. doi: 10.1007/s10072-014-1978-z. Epub 2014 Oct 9. No abstract available.

PMID:
25296987
42.

Crystal structures of free and antagonist-bound states of human α9 nicotinic receptor extracellular domain.

Zouridakis M, Giastas P, Zarkadas E, Chroni-Tzartou D, Bregestovski P, Tzartos SJ.

Nat Struct Mol Biol. 2014 Nov;21(11):976-80. doi: 10.1038/nsmb.2900. Epub 2014 Oct 5.

PMID:
25282151
43.

Aquaporin-1 antibody in neuromyelitis optical patients.

Tüzün E, Tzartos J, Ekizoğlu E, Stergiou C, Zisimopoulou P, Coban A, Shugaiv E, Türkoğlu R, Kürtüncü M, Baykan B, Tzartos S.

Eur Neurol. 2014;72(5-6):271-2. doi: 10.1159/000364904. Epub 2014 Sep 27.

PMID:
25277962
44.

Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.

Skriapa L, Zisimopoulou P, Trakas N, Grapsa E, Tzartos SJ.

J Neuroimmunol. 2014 Nov 15;276(1-2):150-8. doi: 10.1016/j.jneuroim.2014.09.013. Epub 2014 Sep 19.

PMID:
25262156
45.

Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.

Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ.

PLoS One. 2014 Sep 26;9(9):e108327. doi: 10.1371/journal.pone.0108327. eCollection 2014. Erratum in: PLoS One. 2015;10(1):e0117673. PLoS One. 2015 Mar 25;10(3):e0120947.

46.

Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms.

Tsivgoulis G, Dervenoulas G, Kokotis P, Zompola C, Tzartos JS, Tzartos SJ, Voumvourakis KI.

J Neurol Sci. 2014 Nov 15;346(1-2):328-30. doi: 10.1016/j.jns.2014.09.013. Epub 2014 Sep 17.

PMID:
25248951
47.

Purification and functional characterization of a truncated human α4β2 nicotinic acetylcholine receptor.

Kouvatsos N, Niarchos A, Zisimopoulou P, Eliopoulos E, Poulas K, Tzartos S.

Int J Biol Macromol. 2014 Sep;70:320-6. doi: 10.1016/j.ijbiomac.2014.06.058. Epub 2014 Jul 8.

PMID:
25014634
48.

Double seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies.

Tsivgoulis G, Dervenoulas G, Tzartos SJ, Zompola C, Papageorgiou SG, Voumvourakis K.

Muscle Nerve. 2014 Jun;49(6):930-1. doi: 10.1002/mus.24166. No abstract available.

PMID:
24638957
49.

Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice.

Ulusoy C, Kim E, Tüzün E, Huda R, Yılmaz V, Poulas K, Trakas N, Skriapa L, Niarchos A, Strait RT, Finkelman FD, Turan S, Zisimopoulou P, Tzartos S, Saruhan-Direskeneli G, Christadoss P.

Clin Immunol. 2014 Apr;151(2):155-63. doi: 10.1016/j.clim.2014.02.012. Epub 2014 Feb 28.

PMID:
24589747
50.

Parkinson's disease associated with myasthenia gravis and rheumatoid arthritis.

Zis P, Argiriadou V, Temperikidis PP, Zikou L, Tzartos SJ, Tavernarakis A.

Neurol Sci. 2014 May;35(5):797-9. doi: 10.1007/s10072-014-1660-5. Epub 2014 Feb 6. No abstract available.

PMID:
24500521

Supplemental Content

Loading ...
Support Center